Article Details
Retrieved on: 2024-06-11 14:37:29
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the unanimous FDA panel recommendation for the Alzheimer's drug donanemab, relating to the key concept of 'biopharma.' The focus is on amyloidosis and biomarkers, highlighting similar treatments like aducanumab and lecanemab. The tags and concepts are tightly interwoven with the development of drugs targeting amyloid beta plaques, underpinning the biopharma industry's relevance to Alzheimer's disease treatments.
Article found on: www.forbes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here